Nabriva Therapeutics PLC NBRV
We take great care to ensure that the data presented and summarized in this overview for Nabriva Therapeutics plc is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in NBRV
Top Purchases
Top Sells
About NBRV
Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); and XENLETA, a semi-synthetic pleuromutilin antibiotic for the treatment of community-acquired bacterial pneumonia. It also develops XENLETA that is in Phase I clinical trial for the treatment of pediatric infections, as well as sexually transmitted infections, cystic fibrosis, ABSSSI, ventilator-associated bacterial pneumonia, hospital-acquired bacterial pneumonia, osteomyelitis, and prosthetic joint infections. In addition, the company develops CONTEPO, an epoxide antibiotic for use in treating complicated urinary tract infections, as well as is in Phase I clinical trial for peri-operative prophylaxis. The company was formerly known as Nabriva Therapeutics Forschungs GmbH and changed its name to Nabriva Therapeutics plc in 2007. Nabriva Therapeutics plc was incorporated in 2005 and is headquartered in Dublin, Ireland.
Insider Transactions at NBRV
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 29
2023
|
Theodore R Schroeder Director |
SELL
Payment of exercise price or tax liability
|
Direct |
431
-3.47%
|
$431
$1.5 P/Share
|
|
Jan 29
2023
|
Steven P. Gelone Director |
SELL
Payment of exercise price or tax liability
|
Direct |
140
-0.97%
|
$140
$1.5 P/Share
|
|
Jan 06
2023
|
Theodore R Schroeder Director |
SELL
Payment of exercise price or tax liability
|
Direct |
11
-0.09%
|
$11
$1.3 P/Share
|
|
Jan 06
2023
|
Steven P. Gelone Director |
SELL
Payment of exercise price or tax liability
|
Direct |
5
-0.03%
|
$5
$1.3 P/Share
|
|
Dec 31
2022
|
Theodore R Schroeder Director |
SELL
Payment of exercise price or tax liability
|
Direct |
5
-0.04%
|
$5
$1.89 P/Share
|
|
Dec 31
2022
|
Steven P. Gelone Director |
SELL
Payment of exercise price or tax liability
|
Direct |
3
-0.02%
|
$3
$1.89 P/Share
|
|
Dec 06
2022
|
Theodore R Schroeder Director |
SELL
Payment of exercise price or tax liability
|
Direct |
9
-0.07%
|
$18
$2.02 P/Share
|
|
Dec 06
2022
|
Steven P. Gelone Director |
SELL
Payment of exercise price or tax liability
|
Direct |
4
-0.03%
|
$8
$2.02 P/Share
|
|
Nov 30
2022
|
Theodore R Schroeder Director |
SELL
Payment of exercise price or tax liability
|
Direct |
5
-0.04%
|
$10
$2.25 P/Share
|
|
Nov 30
2022
|
Steven P. Gelone Director |
SELL
Payment of exercise price or tax liability
|
Direct |
3
-0.02%
|
$6
$2.25 P/Share
|
|
Nov 06
2022
|
Theodore R Schroeder Director |
SELL
Payment of exercise price or tax liability
|
Direct |
10
-0.08%
|
$20
$2.24 P/Share
|
|
Nov 06
2022
|
Steven P. Gelone Director |
SELL
Payment of exercise price or tax liability
|
Direct |
4
-0.03%
|
$8
$2.24 P/Share
|
|
Oct 31
2022
|
Steven P. Gelone Director |
SELL
Payment of exercise price or tax liability
|
Direct |
3
-0.02%
|
$6
$2.54 P/Share
|
|
Oct 31
2022
|
Theodore R Schroeder Director |
SELL
Payment of exercise price or tax liability
|
Direct |
5
-0.04%
|
$10
$2.54 P/Share
|
|
Oct 06
2022
|
Theodore R Schroeder Director |
SELL
Payment of exercise price or tax liability
|
Direct |
9
-0.07%
|
$18
$2.72 P/Share
|
|
Oct 06
2022
|
Steven P. Gelone Director |
SELL
Payment of exercise price or tax liability
|
Direct |
4
-0.03%
|
$8
$2.72 P/Share
|
|
Sep 30
2022
|
Theodore R Schroeder Director |
SELL
Payment of exercise price or tax liability
|
Direct |
5
-0.04%
|
$10
$2.08 P/Share
|
|
Sep 30
2022
|
Steven P. Gelone Director |
SELL
Payment of exercise price or tax liability
|
Direct |
3
-0.02%
|
$6
$2.08 P/Share
|
|
Sep 06
2022
|
Theodore R Schroeder Director |
SELL
Payment of exercise price or tax liability
|
Direct |
225
-0.07%
|
$0
$0.16 P/Share
|
|
Sep 06
2022
|
Steven P. Gelone Director |
SELL
Payment of exercise price or tax liability
|
Direct |
89
-0.02%
|
$0
$0.16 P/Share
|